Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d39658098ebea577fe2c2b690824345 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_842ba5ba992518de1078de4830ee4be6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_417479ad5f7026462df91620055b7173 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
filingDate |
2014-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfc4bc34fe3e0575de1eb3282819b0dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eeab30b048cb8a47fc929bed16108c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b479394fc63a94b9937679c9b7cc0588 |
publicationDate |
2016-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2016200715-A1 |
titleOfInvention |
Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists |
abstract |
The present invention relates to bicyclic himbacine derivatives of the formula n n n n n n n n n n n n or a pharmaceutically acceptable salt thereof n wherein:n R 1 is n n n n n n n n n n n n n n n n n n n W is n n n n n n n n n n n n n n n n and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD. |
priorityDate |
2013-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |